Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20996801 | 1.00 | FAAH (0.40) | FAAHFFAR1FFAR4GPR84PTPN1 | |
| SCHEMBL19475048 | 0.89 | CNR2 (0.34) | FAAHFFAR1FFAR4 | |
| SCHEMBL20996802 | 0.89 | CNR2 (0.34) | FAAHFFAR1FFAR4 | |
| SCHEMBL19474994 | 0.84 | EPHX2 (0.31) | FAAHFFAR1FFAR4 | |
| SCHEMBL20996805 | 0.84 | EPHX2 (0.31) | FAAHFFAR1FFAR4 | |
| SCHEMBL19475644 | 0.82 | FFAR1 (0.47) | FAAHFFAR1FFAR4GPR84ACACB | |
| SCHEMBL19475641 | 0.82 | FFAR1 (0.47) | FAAHFFAR1FFAR4GPR84ACACB | |
| SCHEMBL10420255 | 0.80 | FFAR1 (0.47) | FAAHFFAR1FFAR4GPR84ACACB | |
| SCHEMBL9842167 | 0.77 | GPR84 (0.44) | FFAR1GPR84 | |
| SCHEMBL19506118 | 0.77 | FFAR1 (0.41) | FAAHFFAR1FFAR4GPR84ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647671-B2 | Promysalin analogues and methods of use thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190161444-A1 | Novel Promysalin Analogues and Methods of Use Thereof | Temple University--of the Commonwealth System of Higher Education | 2019-05-30 | — | — | US | disclosed |
| WO-2017184558-A1 | NOVEL PROMYSALIN ANALOGUES AND METHODS OF USE THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184558-A1 | NOVEL PROMYSALIN ANALOGUES AND METHODS OF USE THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647671-B2 | Promysalin analogues and methods of use thereof | CCL11, MAN2A1, PREP | FAAH 981/4885FFAR1 3682/4885FFAR4 3685/4885 |
| US-20190161444-A1 | Novel Promysalin Analogues and Methods of Use Thereof | MASP2, MAN2A1, CCL11 | FAAH 1130/4885FFAR1 3988/4885FFAR4 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.